ESKIM ® Ethyl esters of polyunsaturated fatty acids

ESKIM ® is a drug based on ethyl esters of polyunsaturated fatty acids (EPA and DHA not less than 85%)

THERAPEUTIC GROUP: Hypolipidemics - Ethyl esters of polyunsaturated fatty acids

ESKIM ® indications

ESKIM ® is indicated as a pharmacological aid in case of hypertriglyceridemia, when a hypolipidic diet plan and other behavioral treatments have not guaranteed a good therapeutic effect.

ESKIM ® can also be used, together with other therapeutic measures, in the secondary prevention of patients with a previous myocardial infarction in order to reduce their mortality.

ESKIM ® action mechanism

The ethyl esters of polyunsaturated fatty acids, taken orally, are absorbed in the intestine in a manner comparable to what happens for all the other lipids taken from the diet. Not being able to circulate freely in the bloodstream, they are conveyed to specific proteins within lipoproteins, which guarantee effective transport at the level of the various tissues. Studies conducted on the pharmacokinetics of polyunsaturated fats have identified lipoproteins with higher density of these nutrients.
The therapeutic effect of ESKIM ® is mainly due to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty acids - intercalated in the cell membrane in the form of phospholipids - can compete with arachidonic acid, as substrates of some important enzymes (desaturases). The result is a reduction in the synthesis of proinflammatory prostaglandins and leukotrienes, but also of platelet aggregates; on the other hand, there is a beneficial increase in anti-inflammatory molecules. This cellular balance, supported by a reduced hepatic synthesis of cholesterol and triglycerides, results in an anti-inflammatory, anti-atherosclerotic and antithrombotic action, capable of reducing the incidence of cardiovascular diseases.

Several studies are still clarifying the various biological mechanisms in which these molecules with pleiotropic capacities are involved, highlighting - among other things - an important antiarrhythmic effect resulting from the stabilization of the cell membranes of myocardiocytes.

Studies carried out and clinical efficacy

OMEGA 3 AND CARDIOVASCULAR EVENTS

BMC Cardiovasc Disord. 2010 Jun 3; 10: 24.

Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials.

Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM.

The literature proposes numerous studies on the efficacy of omega 3 supplementation in the prevention of cardiovascular diseases, with conflicting results. This study, conducted on the evaluation of more than 29 clinical trials (for a total of 35,144 enrolled patients), demonstrates how the intake daily omega 3 could lead to only a modest reduction in mortality, not statistically significant.

2.OMEGA 3 AND TRIGLYCERIDEMIA

Nutr Rev. 2010 Mar; 68: 155-67.

Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides.

Musa-Veloso K, Binns MA, Kocenas AC, Poon T, Elliot JA, Rice H, Oppedal-Olsen H, Lloyd H, Lemke S.

The very high amount of studies in the literature relating to the efficacy of omega 3 therapy has allowed the authors to quantify the hypotryglyceride-lowering action of these molecules. More precisely, the daily intake of doses ranging from 200 to 500mg of EPA and DHA, can guarantee a reduction in plasma triglyceride levels from 3 to 7%.

3. OMEGA 3 IN DIABETIC PATHOLOGY

Diabetes Educ. 2010 Jul-Aug; 36: 565-84. Epub 2010 Jun 9.

Effect of omega-3 fish oil on cardiovascular risk in diabetes.

McEwen B, Morel-Kopp MC, Tofler G, Ward C.

Patients with type II diabetes have a greater risk of developing cardiovascular events, with a significantly higher increase in mortality than the normal population. This meta-analysis study has shown how the intake of omega 3 can lead to a reduction in mortality of about 18%, a reduction in platelet activation, a valuable anti-inflammatory activity, and a balancing of the lipid profile.

Method of use and dosage

ESKIM ® soft capsules of 500mg / 1000mg of ethyl esters of polyunsaturated fatty acids, titrated in EPA and DHA at at least 85% and with a ratio of 0.9 / 1.5: for the treatment of hypertriglyceridemia, up to 3 soft capsules of 1 gram per day could be used, adjusting the dosage according to the results and objectives. Both before and during therapeutic pharmacological treatment, it would be advisable to follow a hypolipidic diet and a correct lifestyle.
In the secondary prevention of heart attack patients, the daily dosage of 1 gram seems to be the most used.

IN ANY CASE, BEFORE TAKING ESKIM ® - YOU NEED THE PRESCRIPTION AND CONTROL OF YOUR DOCTOR.

ESKIM ® warnings

Polyunsaturated fatty acids are nutrients commonly found in nature; therefore, in most cases, they are well tolerated and with a high safety profile. Despite these characteristics, before resorting to the use of a hypotiglyceridemic pharmacological treatment, it would be advisable to follow a low-fat diet and an active lifestyle for at least one quarter.
Given the haemofluidifying and antiplatelet action of these molecules, in order to avoid an increase in bleeding episodes, ESKIM ® should be taken under strict medical supervision in all those patients suffering from coagulation pathologies or in therapy with oral anticoagulants.

PREGNANCY AND BREASTFEEDING

Although there is no specific evidence and clinical trials in this regard, the intake of omega 3 does not appear to have mutagenic and teratogenic effects on the fetus.Despite this, it would be advisable to always consult your doctor and your gynecologist in order to evaluate the correct relationship between risks and benefits.

Interactions

The ethyl esters of polyunsaturated fatty acids contained in ESKIM ® do not seem to interact with active ingredients of various kinds. However, the concomitant intake of anticoagulant drugs could lead to an increase in prothrombin time, with a higher incidence of haemorrhagic events.

Contraindications ESKIM ®

ESKIM ® is contraindicated in case of hypersensitivity to one of its components.

Undesirable Effects - Side Effects

ESKIM ® appears to be well tolerated and free from clinically relevant side effects.
Nausea, vomiting and heartburn appear to be the most described adverse reactions in the literature.

Note

ESKIM ® can only be sold under medical prescription.

The information on ESKIM ® published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.